Ponazuril

Ponazuril

Systematic (IUPAC) name
1-Methyl-3-[3-methyl-4-[4-(trifluoromethylsulfonyl)phenoxy]phenyl]-1,3,5-triazinane-2,4,6-trione
Clinical data
Trade names	Marquis
AHFS/Drugs.com	FDA Professional Drug Information
Legal status	US: ℞-only Veterinary use only
Routes of administration	Oral
Identifiers
CAS Registry Number	69004-04-2
ATCvet code	QP51AJ04
PubChem	CID 3050408
ChemSpider	2312474
UNII	JPW84AS66U Y
Chemical data
Formula	C18H14F3N3O6S
Molecular mass	457.380 g/mol
SMILES CC1=C(C=CC(=C1)N2C(=O)NC(=O)N(C2=O)C)OC3=CC=C(C=C3)S(=O)(=O)C(F)(F)F
InChI InChI=1S/C18H14F3N3O6S/c1-10-9-11(24-16(26)22-15(25)23(2)17(24)27)3-8-14(10)30-12-4-6-13(7-5-12)31(28,29)18(19,20)21/h3-9H,1-2H3,(H,22,25,26) Key:VBUNOIXRZNJNAD-UHFFFAOYSA-N
Y (what is this?)  (verify)

Ponazuril (INN), sold by the Bayer Corporation under the trade name Marquis, is a drug currently approved for the treatment of equine protozoal myeloencephalitis (EPM) in horses, caused by Sarcocystis neurona.^[1][2] More recently, veterinarians have been preparing a formulary version of the medication for use in small animals such as cats and dogs against coccidia, an intestinal parasite. Coccidia treatment is far shorter than treatment for EPM.

See also

• Clazuril
• Diclazuril
• Toltrazuril

References